Table 2.
Health-Related Quality of Life Assessed by the SF-36 According to Liver Disease Severity in Korean Patients with Chronic HCV Infection
| Total HCV-infected patients (n=235) | Chronic hepatitis (n=139) | Compensated LC (n=44) | Decompensated LC (n=9) | Hepatocellular carcinoma (n=41) | Liver transplantation (n=2) | p-value | |
|---|---|---|---|---|---|---|---|
| SF-36 domain score | |||||||
| PF | 76.6±22.8 | 80.6±21.5 | 70.9±25.5 | 65.5±21.0 | 71.7±22.7 | 75.0±0.0 | 0.024 |
| RP | 72.0±30.8 | 74.7±30.9 | 69.6±29.7 | 65.3±29.2 | 66.2±32.4 | 90.7±13.3 | 0.418 |
| BP | 72.3±26.9 | 74.7±25.9 | 65.5±28.8 | 63.2±20.2 | 72.0±28.7 | 100.0±0.0 | 0.131 |
| GH | 53.5±21.7 | 56.7±20.8 | 48.5±20.5 | 29.7±10.2* | 52.4±23.8 | 67.0±29.3 | 0.001 |
| VT | 50.2±24.2 | 52.2±23.4 | 49.3±27.7 | 25.7±14.5* | 48.0±21.8 | 81.3±8.8 | 0.007 |
| SF | 80.2±24.5 | 81.5±24.4 | 81.8±25.1 | 66.7±21.7 | 76.2±24.8 | 93.8±8.8 | 0.289 |
| RE | 77.0±30.5 | 79.8±30.0 | 73.1±32.7 | 60.2±30.8 | 75.2±29.4 | 87.5±17.7 | 0.290 |
| MH | 65.0±23.5 | 67.5±22.3 | 63.2±26.9 | 49.4±26.0 | 62.0±22.2 | 67.5±31.8 | 0.163 |
| SF-36 summary score | |||||||
| PCS | 48.8±8.3 | 50.0±8.1 | 46.6±8.1 | 45.0±6.1 | 47.6±9.0 | 55.3±0.03 | 0.041 |
| MCS | 46.2±11.7 | 47.1±11.5 | 46.0±12.7 | 36.8±11.5 | 45.1±10.7 | 51.8±12.4 | 0.113 |
| EQ-5D profile (11111) | 82 (34.9) | 59 (42.5) | 11 (25.0) | 1 (11.1) | 11 (26.8) | 0 | 0.043 |
| EQ-5D VAS | 67.9±17.8 | 69.5±15.5 | 65.7±20.0 | 58.3±13.7 | 66.3±22.2 | 85±7.1 | 0.148 |
| EQ-5D index | 0.848±0.145 | 0.880±0.105 | 0.775±0.225* | 0.786±0.134 | 0.829±0.123 | 0.910±0.004 | <0.001 |
Data are presented as mean±SD or number (%).
SF-36, Short Form 36; HCV, chronic hepatitis C virus; LC, liver cirrhosis; PF, physical functioning; RP, physical role functioning; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, emotional role; MH, mental health; PCS, physical component summary; MCS, mental component summary; EQ-5D, European quality of life questionnaire-5 dimensions; VAS, visual analogue scale.
p-value <0.05 compared with the chronic hepatitis C group using Scheffe post hoc analysis.
Detailed explanation about tests and a survey license request are available at each website (SF-36, https://campaign.optum.com/content/optum/en/optum-outcomes/what-we-do/health-surveys/sf-36v2-health-survey.html; EQ-5D, https://euroqol.org).